Inventor · disambiguated record
Dave S.B. Hoon
Also filed as: HOON DAVE S · HOON DAVE S B
19 granted patents·42 pending applications·614 citations·filing 1997–2017
94Inventor score
Files withHOON DAVE S B27WAYNE JOHN CANCER INST27FUJIMOTO AKIHIDE1HAIMACHEK INC1HTG MOLECULAR DIAGNOSTICS INC1
Top patents by PatentIndex Score
61 records- 0195US6472375B1DNA vaccine and methods for its useWAYNE JOHN CANCER INST·Filed 1998·Granted Oct 29, 2002·178 cites·33 claims
- 0292US9567640B2Utility of B-RAF DNA mutation in diagnosis and treatment of cancerHOON DAVE S B·Filed 2012·Granted Feb 14, 2017·13 cites·10 claims
- 0392US9556491B2Utility of B-RAF DNA mutation in diagnosis and treatment of cancerHOON DAVE S B·Filed 2008·Granted Jan 31, 2017·14 cites·18 claims
- 0490US6057105ADetection of melanoma or breast metastasis with a multiple marker assayNGI CANCER TECH COMPANY LLC·Filed 1997·Granted May 2, 2000·223 cites·85 claims
- 0588US9410206B2Long noncoding RNA (lncRNA) as a biomarker and therapeutic marker in cancerHOON DAVE S B·Filed 2012·Granted Aug 9, 2016·30 cites·13 claims
- 0683US7910295B2Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimarker quantitative RT-PCRWAYNE JOHN CANCER INST·Filed 2003·Granted Mar 22, 2011·17 cites·18 claims
- 0782US8039218B2Detection of cancer cells in body fluidsWAYNE JOHN CANCER INST·Filed 2005·Granted Oct 18, 2011·2 cites·10 claims
- 0882US7718364B2DNA markers for management of cancerWAYNE JOHN CANCER INST·Filed 2004·Granted May 18, 2010·8 cites·19 claims
- 0980US6465177B1Detection of loss of heterozygosity in tumor and serum of melanoma patientsWAYNE JOHN CANCER INST·Filed 1998·Granted Oct 15, 2002·70 cites·108 claims
- 1080US6432925B1RNA cancer vaccine and methods for its useWAYNE JOHN CANCER INST·Filed 1998·Granted Aug 13, 2002·54 cites·87 claims
- 1177US7851161B2Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancerWAYNE JOHN CANCER INST·Filed 2008·Granted Dec 14, 2010·2 cites·9 claims
- 1274US2015240316A1Use of methylated or unmethylated line-1 dna as a cancer markerWAYNE JOHN CANCER INST·Filed 2014·Application pending·0 cites
- 1372US7588894B2Use of ID4 for diagnosis and treatment of cancerJOHN WAYNE CANCERN INST·Filed 2006·Granted Sep 15, 2009·2 cites·16 claims
- 1472US2009068660A1Use of methylated or unmethylated line-1 dna as a cancer markerWAYNE JOHN CANCER INST·Filed 2008·Application pending·0 cites
- 1569US9758829B2Molecular malignancy in melanocytic lesionsHTG MOLECULAR DIAGNOSTICS INC·Filed 2013·Granted Sep 12, 2017·1 cites·13 claims
- 1667US8288099B2Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancerHOON DAVE S B·Filed 2009·Granted Oct 16, 2012·0 cites·9 claims
- 1766US7888033B2Use of ID4 for diagnosis and treatment of cancerWAYNE JOHN CANCER INST·Filed 2009·Granted Feb 15, 2011·0 cites·20 claims
- 1866US2013345144A1Use of ID4 for Diagnosis and Treatment of CancerHOON DAVE S B·Filed 2009·Application pending·0 cites
- 1964US2015301059A1B7-h3 as a biomarker for diagnosing the progression and early lymph node metastasis of cancerWAYNE JOHN CANCER INST·Filed 2014·Application pending·0 cites
- 2064US2010227319A1Use of runx3 and mir-532-5p as cancer markers and therapeutic targetsWAYNE JOHN CANCER INST·Filed 2009·Application pending·0 cites
- 2163US7897336B2Molecular lymphatic mapping of sentinel lymph nodesWAYNE JOHN CANCER INST·Filed 2003·Granted Mar 1, 2011·0 cites·52 claims
- 2263US2011151465A1Use of methylated or unmethylated line-1 dna as a cancer markerHOON DAVE S B·Filed 2010·Application pending·0 cites
- 2363US2011159510A1Use of methylated or unmethylated line-1 dna as a cancer markerHOON DAVE S B·Filed 2010·Application pending·0 cites
- 2463US2011159502A1Use of methylated or unmethylated line-1 dna as a cancer markerHOON DAVE S B·Filed 2010·Application pending·0 cites
- 2563US2011159501A1Use of methylated or unmethylated line-1 dna as a cancer markerHOON DAVE S B·Filed 2010·Application pending·0 cites
- 2661US2009028866A1USE OF CCR9, CCL25/TECK, AND NITEGRIN alpha4 IN DIAGNOSIS AND TREATMENT OF MELANOMA METASTASIS IN THE SMALL INTESTINEWAYNE JOHN CANCER INST·Filed 2007·Application pending·0 cites
- 2760US2012301477A1USE OF CCR9, CCL25/TECK, AND INTEGRIN alpha4 IN DIAGNOSIS AND TREATMENT OF MELANOMA METASTASIS IN THE SMALL INTESTINEHOON DAVE S B·Filed 2012·Application pending·0 cites
- 2860US2009220980A1Use of methylation status of mint loci and tumor-related genes as a marker for melanoma and breast cancerWAYNE JOHN CANCER INST·Filed 2008·Application pending·0 cites
- 2960US2013231259A1Detection of Micro Metastasis of Melanoma and Breast Cancer in Paraffin-Embedded Tumor Draining Lymph Nodes by Multimarker Quantitative RT-PCRWAYNE JOHN CANCER INST·Filed 2012·Application pending·0 cites
- 3059US7943319B2Utility of RET mutant in diagnosis and treatment of melanomaWAYNE JOHN CANCER INST·Filed 2008·Granted May 17, 2011·0 cites·6 claims
- 3159US7829283B2Methylation of estrogen receptor alpha and uses thereofWAYNE JOHN CANCER INST·Filed 2007·Granted Nov 9, 2010·0 cites·9 claims
- 3257US2011097727A1Dna markers for management of cancerHOON DAVE S B·Filed 2010·Application pending·0 cites
- 3356US2012088683A1Detection of Cancer Cells in Body FluidsHOON DAVE S B·Filed 2011·Application pending·0 cites
- 3455US2011207136A1Detection of Micro Metastasis of Melanoma and Breast Cancer in Paraffin-Embedded Tumor Draining Lymph Nodes by Multimarker Quantitative RT-PCRWAYNE JOHN CANCER INST·Filed 2011·Application pending·0 cites
- 3555US2010330567A1Dna markers for management of cancerHOON DAVE S B·Filed 2010·Application pending·0 cites
- 3655US2011171660A1Use of ccr9, ccl25/teck, and integrin alpha4 in diagnosis and treatment of melanoma metastasis in the small intestineHOON DAVE S B·Filed 2010·Application pending·0 cites
- 3754US2010003689A1Use of Methylation Status of MINT Loci as a Marker for Rectal CancerWAYNE JOHN CANCER INST·Filed 2009·Application pending·0 cites
- 3854US2012148561A1Use of runx3 and mir-532-5p as cancer markers and therapeutic targetsHOON DAVE S B·Filed 2012·Application pending·0 cites
- 3954US2009280479A1Use of free circulating dna for diagnosis, prognosis, and treatment of cancer fundingWAYNE JOHN CANCER INST·Filed 2006·Application pending·0 cites
- 4054US2011206705A1B7-h3 as a biomarker for diagnosing the progression and early lymph node metastasis of cancerHOON DAVE S B·Filed 2010·Application pending·0 cites
- 4153US2011171240A1Use of ccr9, ccl25/teck, and integrin alpha4 in diagnosis and treatment of melanoma metastasis in the small intestineHOON DAVE S B·Filed 2010·Application pending·0 cites
- 4253US2005112604A1Loss of heterozygosity of the DNA markers in the 12q22-23 regionFiled 2004·Application pending·0 cites
- 4352US2011123602A1Molecular lymphatic mapping of sentinel lymph nodesHOON DAVE S B·Filed 2010·Application pending·0 cites
- 4451US2011158975A1Use of runx3 and mir-532-5p as cancer markers and therapeutic targetsHOON DAVE S B·Filed 2010·Application pending·0 cites
- 4551US2015140039A1Immunological markers for adjuvant therapy in melanomaWAYNE JOHN CANCER INST·Filed 2013·Application pending·0 cites
- 4651US2011159509A1Use of runx3 and mir-532-5p as cancer markers and therapeutic targetsHOON DAVE S B·Filed 2010·Application pending·0 cites
- 4750US2007031867A1Molecular/genetic aberrations in surgical margins of resected pancreatic cancer represents neoplastic disease that correlates with disease outcomeWAYNE JOHN CANCER INST·Filed 2006·Application pending·0 cites
- 4850US2016122826A1Use of id4 for diagnosis and treatment of cancerWAYNE JOHN CANCER INST·Filed 2015·Application pending·0 cites
- 4950US2013323740A1Direct blood assay for detection of circulating microrna in cancer patientsHOON DAVE S B·Filed 2013·Application pending·0 cites
- 5048US2008076727A1Utility of high molecular weight melanoma associated antigen in diagnosis and treatment of cancerWAYNE JOHN CANCER INST·Filed 2007·Application pending·0 cites
Showing the top 50 of 61 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Dave S.B. Hoon files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →